Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials

Find Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Near You

Analysis of the Relationship Between Growth Differentiation Factor 15 (GDF-15), Mid Regional proAdrenomedullin (MR proADM), and Persepsin Levels in Patients With Acute Coronary Syndrome With Pneumonia and Chronic Obstructive Pulmonary Disease (COPD) With Influenza Vaccination

Status: Recruiting
Location: See location...
Intervention Type: Drug, Procedure
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The goal of this observational study is to analyze the relationship between various biomarkers (GDF-15, MR proADM, and Presepsin) in patients with Acute Coronary Syndrome (ACS) who also have Pneumonia and Chronic Obstructive Pulmonary Disease (COPD) and have received Influenza vaccinations. The main questions it aims to answer are: * Is there a significant correlation between the levels of these specific biomarkers and the clinical outcomes or inflammatory status of these patients? * How does Influenza vaccinations relate to the levels of these biomarkers in the context of ACS with comorbid respiratory conditions? Researchers will compare the levels of these biomarkers across the participant group to see if they can serve as indicators of the patients' health status or the impact of the vaccinations. Participants will: \- Undergo clinical assessment for Acute Coronary Syndrome, Pneumonia, and COPD. Provide medical history regarding Influenza vaccination status. Provide blood samples for the measurement of GDF-15, MR proADM, and Presepsin levels.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Adult male patients (\< 65 years old).

• History of being an active smoker.

• Confirmed diagnosis of Acute Coronary Syndrome (ACS) and Pneumonia based on clinical, laboratory, and radiological criteria.

• Demonstrated clinical improvement (stabilization) after receiving standard ACS and Pneumonia therapy in the acute intrahospital phase.

• Willing to undergo all study procedures and sign the Informed Consent form.

Locations
Other Locations
Indonesia
RSUD Dr. Saiful Anwar
RECRUITING
Malang
Contact Information
Primary
Martha FA Tatodi, MD
3downdoomdrop@gmail.com
+62895633927741
Backup
Rizky Tania Fadillah, MD
+6281335808012
Time Frame
Start Date: 2026-01-01
Estimated Completion Date: 2026-10-10
Participants
Target number of participants: 60
Treatments
Active_comparator: influenza tetravaccine
influenza tetravaccine 1 dose for each randomized sample
Placebo_comparator: Placebo Group
Placebo group receive 1 dose shot placebo as comparison of the interventional group
Sponsors
Leads: University of Brawijaya

This content was sourced from clinicaltrials.gov